← All indications
Tinea Pedis
Dermatological pruritic lesion in the feet, caused by Trichophyton rubrum, T. mentagrophytes, or Epidermophyton floccosum.
Drugs by status
Approved for this indication (18)
Phase 4 trials (1)
Phase 3 trials (2)
Phase 2 trials (13)
Phase 1 trials (5)
Other trials (6)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (17)
- DPT Laboratories
- Perrigo
- Novartis
- AmDerma
- Biolab Sanus Farmaceutica
- Encube Ethicals Pvt. Ltd.
- Genzum Life Sciences
- Laboratório Teuto Brasileiro S/A
- Therapeutics, Inc.
- Tinea Pharmaceuticals
- Jamaica Hospital Medical Center
- Catawba Clinical Research
- Galeno Desenvolvimento de Pesquisas
- Novum Pharmaceutical Research Services
- Paddington Testing Company
- ACM Global Laboratories
- Johnson and Johnson
Organization Involved with Phase 2 Indications (14)
Organization Involved with Phase 1 Indications (19)
- Stiefel Laboratories
- Pfizer
- GlaxoSmithKline
- The Hong Kong Polytechnic University
- University of Adelaide
- University of Cincinnati
- Taro Pharmaceuticals
- Al Azhar University
- Symbio
- South East Dermatology, South East Dermatology, Carina QLD 4152, Australia
- The Skin Centre, Benowa, Australia
- Skin and Cancer Foundation, Carlton, Australia
- St. George Hospital, Kogarah
- International Dermatology Research Inc.
- Dermatology Specialists, Louisville
- NewLab Clinical Research
- Dr. Cheung Hing Cheong Private Dermatology Clinic
- Douglas Pharmaceuticals
- Apricus Biosciences
Organization Involved with Other Experimental Indications (2)